Loading...
|
Please use this identifier to cite or link to this item:
https://nccur.lib.nccu.edu.tw/handle/140.119/131050
|
| Title: | 企業合併與收購之效益分析
Analysis on the Benefit of the Coherent Mergers and Acquisitions |
| Authors: | 林秀琦
Pinitkitjawat, Napassorn |
| Contributors: | 劉助
Liu, James
林秀琦
Napassorn Pinitkitjawat |
| Keywords: | 合併與收購
必治妥施貴寶
賽爾基因收購案
合併與收購的利益
Mergers and Acquisitions
Bristol Myers Squibb
Celgene Acquisition
Benefit of Mergers and Acquisitions |
| Date: | 2020 |
| Issue Date: | 2020-08-03 17:47:17 (UTC+8) |
| Abstract: | With the disruptive technology and the rapid change in the business environment, the current business environment results in a spike in the M&A activity. But is M&A beneficial to companies? Fundamental analysis on the actual financial performance for pre- and post-M&A of the sample M&A case, Bristol Myers Squibb – Celgene Acquisition is conducted to help determine if this business methodology truly bring about benefits to the companies over the study period. |
| Reference: | Arık, E., & Kutan, A. M. (2015). Do Mergers and Acquisitions Create Wealth Effects? Evidence from Twenty Emerging Markets. Eastern European Economics, 53(6), 529–550. https://doi.org/10.1080/00128775.2015.1099445
Bansal, De Backer, and Ranade. (2018, October 10). What’s behind the pharmaceutical sector’s M&A push. Retrieved from https://www.mckinsey.com/business-functions/strategy-and-corporate-finance/our-insights/whats-behind-the-pharmaceutical-sectors-m-and-a-push
BRISTOL MYERS SQUIBB drug patent status, international patents. (2020, June 15). Retrieved from https://www.drugpatentwatch.com/p/applicant/Bristol%20Myers%20Squibb
Brown, and Elmhirst. (2018, October 3). Few biopharma buyouts in quiet third quarter. Retrieved from https://www.evaluate.com/vantage/articles/data-insights/ma/few-biopharma-buyouts-quiet-third-quarter
Celgene: A Winner in Biopharma. (2015, December 10). Retrieved from https://digital.hbs.edu/platform-rctom/submission/celgene-a-winner-in-biopharma/
Hansell, Kotzen, Olsen, and Farag. (2016, October 25). Bristol-Myers Squibb: Reshaping the Portfolio to Create Superior Shareholder Value. Retrieved from https://www.bcg.com/publications/2016/value-creation-strategy-corporate-development-bristol-myers-squibb.aspx
Health at a Glance 2019: OECD Indicators | en | OECD. (2019, November 7). Retrieved from http://www.oecd.org/health/health-systems/health-at-a-glance-19991312.htm
Kengelbach, Keienburg, Gell, Nielsen, Bader, Degen, and Sievers. (2019, September 25). 2019 Mergers & Acquisitions (M&A) Report: Downturns Are a Better Time for Deal Hunting. Retrieved from https://www.bcg.com/publications/2019/mergers-and-acquisitions-report-shows-downturns-are-a-better-time-for-deal-hunting.aspx
Lobet and van Gampelaere, F. and C. (2018, February 15). Success and Failure in M&A Execution - An Empirical Study — Retrieved from https://gpmip.com/success-and-failure-in-ma-execution-an-empirical-study/
M. Christensen, Alton, Rising, and Waldeck. (2011, March). The Big Idea: The New M&A Playbook. Retrieved from https://hbr.org/2011/03/the-big-idea-the-new-ma-playbook
M. Szmigiera. (2020, February 24). Value of M&A deals globally 1985-2019. Retrieved from https://www.statista.com/statistics/267369/volume-of-mergers-and-acquisitions-worldwide/
Melicher, R. W., & Norton, E. A. (2013). Introduction to Finance (15th ed.). Hoboken, NJ, United States: Wiley.
NCHS. (2010, September). Products - Data Briefs - Number 42 - September 2010. Retrieved from https://www.cdc.gov/nchs/products/databriefs/db42.htm
PMGroup Worldwide Limited. (2020, April 1). Pharma funding and M&A in 2020. Retrieved from http://www.pmlive.com/pharma_intelligence/Pharma_funding_and_M_and_A_in_2020_1328712
Roser, Ortiz-Ospina and Ritchie. (2019, October). Life Expectancy. Retrieved from https://ourworldindata.org/life-expectancy
Taylor, A. (2019, August 22). How to Measure M&A Success. Retrieved from https://hingemarketing.com/blog/story/how-to-measure-ma-success
Torjesen, I. (2015, May 12). Drug development: the journey of a medicine from lab to shelf. Retrieved from https://www.pharmaceutical-journal.com/publications/tomorrows-pharmacist/drug-development-the-journey-of-a-medicine-from-lab-to-shelf/20068196.article?firstPass=false
Trefis Team. (2019, January 7). Why Is Celgene A Strategic Fit For Bristol-Myers Squibb. Retrieved from https://www.forbes.com/sites/greatspeculations/2019/01/07/why-is-celgene-a-strategic-fit-for-bristol-myers-squibb/#38bc850e76c2
Vitez and Harrison. (2016, December 8). Trends in pharmaceutical mergers and acquisitions. Retrieved from https://biopharmadealmakers.nature.com/users/9880-biopharma-dealmakers/posts/13880-trends-in-pharmaceutical-mergers-and-acquisitions
Weintraub, A. (2020, March 26). Bristol Myers nabs long-sought FDA nod for Celgene’s MS drug ozanimod, but pandemic delays launch. Retrieved from https://www.fiercepharma.com/pharma/bristol-myers-investors-breathe-a-sigh-relief-as-fda-approves-celgene-s-ms-drug-ozanimod |
| Description: | 碩士
國立政治大學
國際經營管理英語碩士學位學程(IMBA)
107933045 |
| Source URI: | http://thesis.lib.nccu.edu.tw/record/#G0107933045 |
| Data Type: | thesis |
| DOI: | 10.6814/NCCU202000993 |
| Appears in Collections: | [國際經營管理英語碩士學程IMBA] 學位論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| 304501.pdf | | 2468Kb | Adobe PDF2 | 75 | View/Open |
|
All items in 政大典藏 are protected by copyright, with all rights reserved.
|
